Clinical Trials
Overview
We are committed to developing curative allogeneic cell therapies through rigorous clinical trials that assess the safety and efficacy of our investigational medicines for patients with cancer and autoimmune diseases. We are dedicated to upholding the highest standards throughout our trials to ensure patient safety and well-being are prioritized, and are grateful to the patients, families, hospitals and clinics that participate in our clinical studies.
Current Trials
ELiPSE-1: Phase 1 Clinical Trial
A multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CNTY-101 in patients with relapsed or refractory CD19-positive B-cell lymphomas.
Learn more about Century’s current Phase 1 clinical trial, ELiPSE-1, with study ID number: NCT05336409 at clinicaltrials.gov.
CALiPSO-1: Phase 1 Clinical Trial
A multicenter, dose-finding study to evaluate the safety and efficacy of CNTY-101 in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy and diffuse cutaneous systemic sclerosis.
Now Recruiting
Learn more about Century’s current Phase 1 clinical trial, CALiPSO-1, with study ID number: NCT06255028 at clinicaltrials.gov.